BioReference initiates COVID-19 testing for all Major League Soccer players, match officials, and Club and League employees participating in the MLS is Back Tournament
MLS will support COVID-19 antibody testing for the Orlando community utilizing BioReference’s community collection program
ELMWOOD PARK, N.J., July 09, 2020 – BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), will conduct COVID-19 testing for all Major League Soccer (MLS) players as well as match officials, and Club and League staff participating in the MLS is Back Tournament. MLS has chosen BioReference as its laboratory to assist in informing its return-to-play policies for the Tournament kicking off in Orlando in early July.
In addition to providing testing to players, match officials, and staff, MLS is working with BioReference to provide COVID-19 antibody testing to the Orlando community. MLS is supporting the latest community collection location at the Orlando Vineland Premium Outlets, which began on July 6. The collection location is open Mondays through Saturdays from 8:00 AM to 6:00 PM ET.
“We are honored to be providing testing solutions to Major League Soccer as it prepares to restart its season,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “The leadership of MLS worked diligently with us to develop a COVID-19 PCR and antibody testing strategy with the goal of providing the safest possible environment for the players, coaches and staff to begin to play again.”
For more information, visit https://www.bioreference.com/coronavirus/employers-and-government-authorities/.
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. BioReference has been working expeditiously to develop and offer test services that will yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 120 M.D., Ph.D. and other professional level clinicians and scientists. With a leading position in the areas of genetics, women’s health, maternal fetal medicine, oncology and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine. For more information, visit www.bioreference.com.
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as “expects,” “plans,” “projects,” “will,” “may,” “anticipates,” “believes,” “should,” “intends,” “estimates,” and other words of similar meaning, including statements regarding BioReference’s antibody screening test, the availability of the test and the role and value of the information provided and its impact on decisions relative to the safety of employees and customers, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in the OPKO Health, Inc. Annual Reports on Form 10-K filed and to be filed with the Securities and Exchange Commission and in its other filings with the Securities and Exchange Commission. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Media contact for BioReference Laboratories:
Hillary Titus, email@example.com